Sarepta would have to conduct new studies to get back on market, FDA official says

Sarepta Therapeutics would need to conduct new studies to show the FDA that its Duchenne muscular dystrophy therapy Elevidys is safe, a senior FDA official told Endpoints News, amid what they described as unanimous agreement ...